First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
The transaction is expected to close in the Q4FY22
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Subscribe To Our Newsletter & Stay Updated
